1型人类免疫缺陷病毒群抗原作为抗病毒治疗的靶点。
HIV type 1 Gag as a target for antiviral therapy.
作者信息
Waheed Abdul A, Freed Eric O
机构信息
Virus-Cell Interaction Section, HIV Drug Resistance Program, National Cancer Institute, Frederick, Maryland 21702-1201, USA.
出版信息
AIDS Res Hum Retroviruses. 2012 Jan;28(1):54-75. doi: 10.1089/AID.2011.0230. Epub 2011 Sep 21.
Abstract
The Gag proteins of HIV-1 are central players in virus particle assembly, release, and maturation, and also function in the establishment of a productive infection. Despite their importance throughout the replication cycle, there are currently no approved antiretroviral therapies that target the Gag precursor protein or any of the mature Gag proteins. Recent progress in understanding the structural and cell biology of HIV-1 Gag function has revealed a number of potential Gag-related targets for possible therapeutic intervention. In this review, we summarize our current understanding of HIV-1 Gag and suggest some approaches for the development of novel antiretroviral agents that target Gag.
摘要
HIV-1的Gag蛋白是病毒颗粒组装、释放和成熟过程中的核心参与者，在建立有效感染中也发挥作用。尽管它们在整个复制周期中都很重要，但目前尚无批准的针对Gag前体蛋白或任何成熟Gag蛋白的抗逆转录病毒疗法。在理解HIV-1 Gag功能的结构和细胞生物学方面的最新进展揭示了一些可能用于治疗干预的潜在Gag相关靶点。在这篇综述中，我们总结了目前对HIV-1 Gag的理解，并提出了一些开发靶向Gag的新型抗逆转录病毒药物的方法。
相似文献
1
HIV type 1 Gag as a target for antiviral therapy.
AIDS Res Hum Retroviruses. 2012 Jan;28(1):54-75. doi: 10.1089/AID.2011.0230. Epub 2011 Sep 21.
2
New therapeutic approaches targeted at the late stages of the HIV-1 replication cycle.
Curr Med Chem. 2011;18(1):16-28. doi: 10.2174/092986711793979751.
3
HIV-1 Gag as an Antiviral Target: Development of Assembly and Maturation Inhibitors.
Curr Top Med Chem. 2016;16(10):1154-66. doi: 10.2174/1568026615666150902102143.
4
[The role of structural protein Gag and related gene (protein) in late stages of the HIV-1 replication cycle and the inhibitors].
Yao Xue Xue Bao. 2010 Feb;45(2):205-14.
5
Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain.
J Virol. 2000 May;74(10):4621-33. doi: 10.1128/jvi.74.10.4621-4633.2000.
6
The prototype HIV-1 maturation inhibitor, bevirimat, binds to the CA-SP1 cleavage site in immature Gag particles.
Retrovirology. 2011 Dec 7;8:101. doi: 10.1186/1742-4690-8-101.
7
Virus maturation as a new HIV-1 therapeutic target.
Expert Opin Ther Targets. 2009 Aug;13(8):895-908. doi: 10.1517/14728220903039714.
8
Structure-Activity Relationships of the Human Immunodeficiency Virus Type 1 Maturation Inhibitor PF-46396.
J Virol. 2016 Aug 26;90(18):8181-97. doi: 10.1128/JVI.01075-16. Print 2016 Sep 15.
9
Entry inhibitors directed towards glycoprotein gp120: an overview on a promising target for HIV-1 therapy.
Curr Med Chem. 2013 Feb 1;20(6):751-71.
10
Novel postentry inhibitor of human immunodeficiency virus type 1 replication screened by yeast membrane-associated two-hybrid system.
Antimicrob Agents Chemother. 2011 Sep;55(9):4251-60. doi: 10.1128/AAC.00299-11. Epub 2011 Jul 11.
引用本文的文献
1
Disruption of Transmembrane Phosphatidylserine Asymmetry by HIV-1 Incorporated SERINC5 Is Not Responsible for Virus Restriction.
Biomolecules. 2024 May 10;14(5):570. doi: 10.3390/biom14050570.
2
Small molecules modulating RNA splicing: a review of targets and future perspectives.
RSC Med Chem. 2024 Jan 11;15(4):1109-1126. doi: 10.1039/d3md00685a. eCollection 2024 Apr 24.
3
HMMPolish: a coding region polishing tool for TGS-sequenced RNA viruses.
Brief Bioinform. 2023 Sep 20;24(5). doi: 10.1093/bib/bbad264.
4
Temporal control by cofactors prevents kinetic trapping in retroviral Gag lattice assembly.
Biophys J. 2023 Aug 8;122(15):3173-3190. doi: 10.1016/j.bpj.2023.06.021. Epub 2023 Jun 30.
5
Exosome-Based Vaccines: History, Current State, and Clinical Trials.
Front Immunol. 2021 Jul 14;12:711565. doi: 10.3389/fimmu.2021.711565. eCollection 2021.
6
Nano-Microparticle Platforms in Developing Next-Generation Vaccines.
Vaccines (Basel). 2021 Jun 5;9(6):606. doi: 10.3390/vaccines9060606.
7
An insight on promising strategies hoping to cure HIV-1 infection by targeting Rev protein-short review.
Pharmacol Rep. 2021 Oct;73(5):1265-1272. doi: 10.1007/s43440-021-00257-9. Epub 2021 Apr 11.
8
Emergence of a Novel Protease Inhibitor Resistance Signature in HIV-1 Matrix.
mBio. 2020 Nov 3;11(6):e02036-20. doi: 10.1128/mBio.02036-20.
9
Molecular genotypes of gag sequences in HIV-1 infected children treated with antiretroviral therapy in Vietnam.
Ther Adv Infect Dis. 2020 Sep 17;7:2049936120958536. doi: 10.1177/2049936120958536. eCollection 2020 Jan-Dec.
10
The Interplay between HIV-1 Gag Binding to the Plasma Membrane and Env Incorporation.
Viruses. 2020 May 16;12(5):548. doi: 10.3390/v12050548.
本文引用的文献
1
HIV Nuclear Entry: Clearing the Fog.
Viruses. 2010 May;2(5):1190-1194. doi: 10.3390/v2051190. Epub 2010 May 11.
2
Correlative structural biology: how to investigate the fine details of viral structure.
Viruses. 2010 Jan;2(1):107-110. doi: 10.3390/v2010107. Epub 2010 Jan 11.
3
HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation.
J Mol Biol. 2011 Jul 22;410(4):582-608. doi: 10.1016/j.jmb.2011.04.042.
4
Evidence of a role for soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) machinery in HIV-1 assembly and release.
J Biol Chem. 2011 Aug 26;286(34):29861-71. doi: 10.1074/jbc.M111.241521. Epub 2011 Jun 16.
5
Complementary assays reveal a relationship between HIV-1 uncoating and reverse transcription.
Proc Natl Acad Sci U S A. 2011 Jun 14;108(24):9975-80. doi: 10.1073/pnas.1014522108. Epub 2011 May 31.
6
Antiviral activity of α-helical stapled peptides designed from the HIV-1 capsid dimerization domain.
Retrovirology. 2011 May 3;8:28. doi: 10.1186/1742-4690-8-28.
7
Atomic-level modelling of the HIV capsid.
Nature. 2011 Jan 20;469(7330):424-7. doi: 10.1038/nature09640.
8
Hexagonal assembly of a restricting TRIM5alpha protein.
Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):534-9. doi: 10.1073/pnas.1013426108. Epub 2010 Dec 27.
9
Phosphoinositides direct equine infectious anemia virus gag trafficking and release.
Traffic. 2011 Apr;12(4):438-51. doi: 10.1111/j.1600-0854.2010.01153.x. Epub 2011 Feb 1.
10
HIV capsid is a tractable target for small molecule therapeutic intervention.
PLoS Pathog. 2010 Dec 9;6(12):e1001220. doi: 10.1371/journal.ppat.1001220.
Zotero 插件